Lincoln Pharmaceuticals Limited (LINCOLN) fundamentals
Lincoln Pharmaceuticals Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as LINCOLN (ISIN INE405C01035). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Lincoln Pharmaceuticals Limited does
Lincoln Pharmaceuticals Limited is engaged in the business of manufacturing and trading pharmaceutical products, as well as undertaking contract manufacturing from pharmaceuticals companies across India and the globe. The Company’s product categories include tablets, capsules, liquid injection, cream in tubes, eye/ear drops, dry power injection, SVP injectables, dry-powder suspensions, liquid injection, and pharma products. It offers products for anti-infective, respiratory system, gynecology, cardio and CNS (central nervous system), antibacterial, dermatological infection, anti-diabetic, and anti-malaria. The Company is also engaged in building a portfolio of lifestyle and chronic segments, primarily in women’s healthcare and dermatology. The Company caters to approximately 60 countries in Europe, Latin America, Africa, Asia Pacific, Southeast Asia, and 26 states across India. The Company has two manufacturing facilities located in Mehsana and Khatraj, Gujarat.
Valuation and market data
| Last close | ₹636.70 |
|---|---|
| Market capitalisation | ₹1,275 crore |
| Enterprise value | ₹1,281 crore |
| P/E (TTM) | 0.00 |
| Price to book | 1.90 |
| Price to sales (TTM) | 1.73 |
| Book value per share | ₹335.30 |
| Dividend yield | 28.27% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Thu Dec 17 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹704 crore | ₹116 crore | ₹88 crore | 0.00 |
| Mar 2025 | ₹646 crore | ₹109 crore | ₹82 crore | 41.11 |
| Mar 2024 | ₹615 crore | ₹122 crore | ₹93 crore | 46.58 |
| Mar 2023 | ₹533 crore | ₹100 crore | ₹73 crore | 36.40 |
| Mar 2022 | ₹482 crore | ₹96 crore | ₹69 crore | 34.63 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 49.8% |
|---|---|
| Foreign institutions (FII) | 4.6% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.3% |
| Retail and others | 45.4% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.